雷替曲塞联合伊利替康一线治疗晚期结直肠癌的临床研究

目的 评价雷替曲塞联合伊立替康(CPT-11)治疗晚期结直肠癌的疗效和不良反应.方法 将59例晚期初治结直肠癌患者随机分为治疗组(31例)和对照组(28例).治疗组采用雷替曲塞+CPT-11方案治疗,对照组采用CPT-11+5-FU+LV方案治疗.结果 治疗组和对照组的有效率分别为41.9％和17.9％,差异有统计学意义(P＜0.05)；疾病控制率分别为87.1％和64.3％,差异有统计学意义(P＜0.05).两种治疗方案的不良反应发生率比较无明显差异.结论 雷替曲塞联合CPT-11作为一线方案治疗晚期结直肠癌是有效的.

CLINICAL STUDY ON THE COMBINED USE OF RALTITREXED AND IRI-NOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL CANCER

Objective To evaluate the curative effect and the adverse effect of the combined use of raltitrexed and irinotecan in the treatment of advanced colorectal cancer(CRC).Methods 59 cases of advanced CRC patients were randomly divided into the treatment group(31 cases) and the control group(28 cases) after the primary treatment.The treatment group was treated with raltitrexed and irinotecan,while the control group was treated with irinotecan,5-fluorouracil and leucovorin.Results The effective rates of the treatment group and the control group were 41.9% and 17.9% respectively(P<0.05),and the rates of disease control of the treatment group and the control group were 87.1% and 64.3% respectively(P<0.05).No significant difference in adverse effect was found between the two groups.Conclusion The combined use of raltitrexed and irinotecan can produce good curative effect on advanced CRC.